Stockscreener 앱 받기
1.40
3.70%
0.05
전일 마감가:
$1.35
열려 있는:
$1.36
하루 거래량:
4.31M
Relative Volume:
1.38
시가총액:
$1.11B
수익:
$711.41M
순이익/손실:
$-133.73M
주가수익비율:
-7.3684
EPS:
-0.19
순현금흐름:
$-199.99M
1주 성능:
+4.48%
1개월 성능:
+8.53%
6개월 성능:
-6.67%
1년 성능:
-6.04%
1일 변동 폭
$1.35
$1.43
1주일 범위
$1.32
$1.43
52주 변동 폭
$1.21
$2.035
Opko Health Inc Stock (OPK) Company Profile
명칭
Opko Health Inc
전화
305-575-4181
주소
4400 BISCAYNE BLVD., MIAMI, FL
OPK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.40 | 1.06B | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
404.94 | 160.56B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
188.07 | 141.52B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
520.87 | 42.74B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
112.04 | 34.11B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
158.96 | 27.70B | 15.50B | 1.33B | 2.16B | 7.34 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-25 | 개시 | JP Morgan | Neutral |
| 2023-06-29 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-01-24 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2021-06-21 | 개시 | Ladenburg Thalmann | Buy |
| 2019-11-25 | 개시 | Piper Jaffray | Overweight |
| 2018-03-02 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2016-06-21 | 재확인 | Standpoint Research | Buy |
| 2016-06-03 | 개시 | Standpoint Research | Buy |
| 2016-03-31 | 재확인 | Barrington Research | Outperform |
| 2015-10-16 | 개시 | JP Morgan | Overweight |
| 2015-09-11 | 다운그레이드 | Jefferies | Buy → Hold |
| 2015-03-03 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2014-05-12 | 재확인 | Oppenheimer | Outperform |
| 2014-03-14 | 개시 | Oppenheimer | Outperform |
| 2013-11-13 | 재확인 | Ladenburg Thalmann | Buy |
| 2013-05-30 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-10-22 | 개시 | Barrington Research | Outperform |
| 2011-12-01 | 재확인 | Ladenburg Thalmann | Buy |
| 2011-07-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Opko Health Inc 주식(OPK)의 최신 뉴스
What drives OPKO Health Inc. stock priceConsistently high yield - jammulinksnews.com
What analysts say about OPKO Health Inc. stockSkyrocketing returns - Autocar Professional
Is OPKO Health Inc. a good long term investmentOutstanding yields - Autocar Professional
OPKO Health Inc. Stock Analysis and ForecastFree Consultation - jammulinksnews.com
OPKO Health (NASDAQ:OPK) Stock Rating Upgraded by LADENBURG THALM/SH SH - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) Receives $2.75 Consensus Price Target from Analysts - MarketBeat
H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3 - MSN
Opko Health (OPK) Has a New Rating from Ladenburg Thalmann & Co. - The Globe and Mail
Capital Advisors Inc. OK Increases Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health and Entera Bio Announce Abstract on PK/PD of - GlobeNewswire
OPKO Health and Entera Bio abstract selected for ESPEN Congress - StreetInsider
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress - Yahoo Finance
Breakthrough: First-Ever Oral Tablet Could Replace Daily Injections for Short Bowel Syndrome Treatment - Stock Titan
Investor Network: OPKO Health, Inc. to Host Earnings Call - ACCESS Newswire
OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025 - MSN
OPKO Health's Russell 2000 Defensive Index Inclusion: A Catalyst for Strategic Revaluation - AInvest
10 Best Healthcare Penny Stocks to Buy According to Analysts - Insider Monkey
OPKO and Entera to present data on oral obesity treatment at ENDO 2025 - Investing.com Nigeria
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting - OPKO Health, Inc.
Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT - Yahoo Finance
13 Best Long-Term Penny Stocks to Buy According to Analysts - Insider Monkey
Shareholders in OPKO Health (NASDAQ:OPK) have lost 51%, as stock drops 6.5% this past week - simplywall.st
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN
Quote - OPKO Health, Inc.
Bone Cancer Drugs Market Set to Witness Significant Growth - openPR.com
Bank of America Corp DE Has $855,000 Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy (NASDAQ:OPK) - Seeking Alpha
ModeX assembles advisory board for antibody development By Investing.com - Investing.com India
ModeX assembles advisory board for antibody development - Investing.com
OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - The Manila Times
OPKO Health's (OPK) ModeX Therapeutics Forms Scientific Advisory Board - StreetInsider
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - GlobeNewswire
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - GlobeNewswire Inc.
Nuveen Asset Management LLC Boosts Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
BNP Paribas Financial Markets Cuts Position in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) Shares Purchased by Two Sigma Investments LP - MarketBeat
Peptide Therapeutics Market Growth Set to Surge Significantly - openPR.com
Opko health outlines $675M-$685M revenue guidance for 2025 amid strategic initiatives - MSN
Opko Health Inc (OPK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.04%
1.25%
자본화:
|
볼륨(24시간):